Letter
Medicine, General & Internal
H. Franklin Bunn
Summary: The trials show convincing evidence that vadadustat is effective in treating anemia in patients with chronic kidney disease, compared to darbepoetin alfa which has prolonged life span in circulation.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Urology & Nephrology
Violante Olivari, Simona Maria Di Modica, Maria Rosa Lidonnici, Mariam Aghajan, Celia Cordero-Sanchez, Emanuele Tanzi, Mariateresa Pettinato, Alessia Pagani, Francesca Tiboni, Laura Silvestri, Shuling Guo, Giuliana Ferrari, Antonella Nai
Summary: Anemia, a common complication of systemic inflammation, is influenced by cytokines, hepatic hormone, and iron metabolism. Anemia of chronic kidney disease (CKD) is a distinct form of inflammatory anemia, and traditional therapy based on increased erythropoietin (EPO) is limited. Hematopoietic and hepatic targeting of transferrin receptor 2 (Tfr2) can improve anemia by promoting erythropoiesis and increasing iron supply. Thus, combined targeting of hematopoietic and hepatic Tfr2 may be a potential therapeutic option.
KIDNEY INTERNATIONAL
(2023)
Article
Medicine, General & Internal
Hirotaka Fukasawa, Ryuichi Furuya, Mai Kaneko, Daisuke Nakagami, Yuri Ishino, Shuhei Kitamoto, Kyosuke Omata, Hideo Yasuda
Summary: Zinc is essential for various physiological processes in humans, and its deficiency can lead to impaired growth, immune function, taste maintenance, and neurological function. Patients with chronic kidney disease are at risk of zinc deficiency, which is associated with anemia, nutritional problems, cardiovascular diseases, and non-specific symptoms. Zinc supplementation may be beneficial, but it can cause copper deficiency and severe disorders. This review focuses on the roles of zinc and its association with complications in CKD patients.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Nutrition & Dietetics
Juan F. Navarro-Gonzalez, Carmen Mora-Fernandez, Juan Miguel Diaz-Tocados, Milica Bozic, Marcelino Bermudez-Lopez, Marisa Martin, Jose Manuel Valdivielso
Summary: This study found that elevated serum phosphate and intact FGF23 levels were closely associated with an increased risk of anemia in patients with chronic kidney disease. Low phosphate levels amplified the effect of intact FGF23 concentration on anemia.
Article
Cell Biology
Li Zhang, Jie Hou, Jia Li, Sen-Sen Su, Shuai Xue
Summary: Roxadustat elevated serum Hb levels significantly compared to placebo in NDD patients, but not in dialysis-dependent patients. The drug showed a higher Hb response rate in NDD patients compared to placebo. Roxadustat is a safe and effective treatment for anemia in CKD patients.
Article
Biochemistry & Molecular Biology
Gabriel Rufino Estrela, Leandro Ceotto Freitas-Lima, Alexandre Budu, Adriano Cleis de Arruda, Mauro Sergio Perilhao, Ricardo Ambrosio Fock, Jonatan Barrera-Chimal, Ronaldo Carvalho Araujo
Summary: This study established three mouse models of CKD-induced anemia, showing that anemia can be induced regardless of the mechanism and severity of kidney injury.
Article
Endocrinology & Metabolism
Li-Ping Yang, Jin-Wei Wang, Ming Zhu, Bi-Xia Gao, Fang Wang, Kevin He, Shen Li, Lu-Xia Zhang, Ming-Hui Zhao
Summary: This study evaluated the association of serum phosphorus with hemoglobin level and its longitudinal variation in patients with chronic kidney disease. The results indicated that serum phosphorus level was negatively associated with hemoglobin level and was independently associated with anemia prevalence and longitudinal variation of hemoglobin.
JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS
(2023)
Article
Transplantation
Ahmed A. Awan, Carl P. Walther, Peter A. Richardson, Maulin Shah, Wolfgang C. Winkelmayer, Sankar D. Navaneethan
Summary: In patients with chronic kidney disease and anemia, absolute and functional iron deficiency anemia were associated with various clinical covariates. Functional IDA was linked to an increased risk of mortality and cardiovascular hospitalization, while absolute IDA was only associated with a higher risk of hospitalization.
NEPHROLOGY DIALYSIS TRANSPLANTATION
(2021)
Article
Endocrinology & Metabolism
Alain K. Koyama, Elizabeth Lundeen, Kai McKeever Bullard, Meda E. Pavkov
Summary: This study investigated the prevalence of anemia among adults with diabetes in the United States and evaluated the impact of chronic kidney disease (CKD) and anemia on all-cause mortality. The results showed that anemia and CKD were significantly associated with all-cause mortality, and the risk of death was even higher for individuals with both conditions. This suggests that anemia may be an important predictor of death among adults with diabetes.
DIABETES RESEARCH AND CLINICAL PRACTICE
(2023)
Article
Geriatrics & Gerontology
Osman Kara, Pinar Soysal, Muharrem Kiskac, Lee Smith, Abdulkadir Karismaz, Rumeyza Kazancioglu
Summary: The aim of this study was to determine target hemoglobin levels in older patients with chronic kidney disease (CKD) and their impact on geriatric assessment parameters. The results showed that anemia was associated with decreased muscle strength, increased risk of falls, and decreased functional capacity. Therefore, maintaining hemoglobin levels within the range of 11.8-12.1 for older females with CKD and 12.6-12.8 for older males with CKD is important.
AGING CLINICAL AND EXPERIMENTAL RESEARCH
(2022)
Review
Pharmacology & Pharmacy
Qiyan Zheng, Yahui Wang, Huisheng Yang, Luying Sun, Xinwen Fu, Ruojun Wei, Yu Ning Liu, Wei Jing Liu
Summary: Daprodustat showed significant efficacy in treating anemia of chronic kidney disease patients, with no serious adverse events observed. It demonstrated favorable outcomes compared to placebo and rhEPO in terms of hemoglobin levels.
FRONTIERS IN PHARMACOLOGY
(2021)
Review
Medicine, General & Internal
Tomas Ganz, Francesco Locatelli, Mustafa Arici, Tadao Akizawa, Michael Reusch
Summary: Roxadustat has a distinct impact on iron parameters and hemoglobin levels compared to erythropoiesis-stimulating agents (ESAs). It decreases serum ferritin levels to a greater extent and increases serum iron levels instead of decreasing them. The decrease in transferrin saturation in patients treated with Roxadustat is relatively small and is not observed in non-dialysis or dialysis-dependent chronic kidney disease (CKD) patients by Week 52. Roxadustat improves iron availability, increases erythropoiesis, and requires less intravenous iron use compared to placebo and ESA. Hepcidin levels generally decrease more significantly with Roxadustat than with ESA or placebo. The mechanisms underlying the effects of Roxadustat and ESAs on iron availability, stores, and erythropoiesis differ and should be considered holistically when treating CKD anemia.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Medicine, General & Internal
Filagot Bishaw, Maekel Belay Woldemariam, Gashahun Mekonen, Bezawit Birhanu, Abinet Abebe
Summary: Anemia is common in patients with chronic kidney disease (CKD) and is associated with negative outcomes. This study aimed to determine the prevalence of anemia and its predictors in CKD patients in Jimma, Ethiopia. A total of 150 CKD patients were included in the study, and the prevalence of anemia was found to be 85.33%. Stage 4 and stage 5 CKD, as well as a CKD duration of less than 1 year, were significantly associated with anemia. The high prevalence of anemia in CKD patients emphasizes the need for regular follow-up and intervention.
Review
Urology & Nephrology
Henry H. L. Wu, Rajkumar Chinnadurai
Summary: ESA hyporesponsiveness, defined as no increase in hemoglobin concentration from baseline after the first month of treatment on appropriate weight-based dosing, is associated with factors such as iron deficiency, inflammation, and uremia. There is ongoing debate on determining a standard treatment pathway for managing ESA hyporesponsiveness. The development of new treatments like hypoxia-inducing factor-stabilizers may offer new insights in managing this condition.
Article
Plant Sciences
Min Gao, Zejun Zhang, Yiming Zhang, Minghui Li, Xiaoyan Che, Xiuming Cui, Mei Wang, Yin Xiong
Summary: This study demonstrated that steamed Panax notoginseng can ameliorate renal anemia by promoting overall hematopoiesis and inhibiting the progress of renal injury in mice.
JOURNAL OF ETHNOPHARMACOLOGY
(2022)